Abingdon Extends Strategic Alliance with Stason Pharmaceuticals
Abingdon Life Sciences and Stason Pharmaceuticals have extended their strategic alliance, which was originally announced on August 4th 2008.
ABINGDON LIFE SCIENCES, INC. EXTENDS STRATEGIC ALLIANCE WITH STASON PHARMACEUTICALS, INC. TO PROVIDE REGULATORY AND CLINICAL SUPPORT TO ASIAN PHARMACEUTICAL AND BIOTECH COMPANIES.
Carlsbad, CA, November 17th 2008: Abingdon Life Sciences, Inc. and Stason Pharmaceuticals, Inc have extended their strategic alliance announced on August 4th 2008. Abingdon will utilize the resources of Stason Pharma Japan Co. Ltd. to enhance their business development and IP licensing opportunities in Asia. Abingdon will also offer strategic planning, clinical development and regulatory science support for companies in Japan and throughout Asia wishing to register pharmaceuticals, biotech products and medical devices in the United States via Stason Pharma Japan.
“This expansion will compliment Abingdon’s continued growth within the US and is a major step forward in the current economical climate. Our relationship with Stason has been beneficial for both companies and we believe this expansion will further strengthen the alliance”, said Richard Lebovitz, Abingdon CEO. Hiro Hirota, President, Stason Pharma Japan added “Abingdon’s strategic expansion is good news for many Japanese pharmaceutical and biotech companies who need clinical and regulatory support for their business expansion into the US market. Stason Pharma Japan will be playing an important role to develop new business opportunities between Abingdon and Asian companies, particularly in Japan”.
About Abingdon Life Sciences, Inc.:
Abingdon Life Sciences, Inc. is a first-in-class Drug and Device Development Management Organization (DDMO) providing drug and device companies superior clinical and regulatory services based on an integrated strategic development model. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience.
About Stason Pharmaceuticals, Inc.:
Founded in 1994, Stason Pharmaceuticals, Inc. has evolved into a vertically integrated cGMP contract development organization with affiliates and locations in Texas, Massachusetts, Japan, China and Taiwan that provide complete turn-key drug development solutions for API, prototype and final product, clinical supplies for all phases, and commercial production and distribution. Stason also out-licenses internally developed technologies to companies worldwide. Stason is specialized in developing and processing high-potency products, including oncology drugs.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
